<i>In vivo</i> assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3
Jana Schmidt(University of Tübingen), Olaf Rieß(STZ eyetrial), Matthias Golla(University of Tübingen), Thorsten Schmidt(University of Tübingen), Lisa Soleymani Lehmann(Brigham and Women's Hospital), Jonasz Jeremiasz Weber(University Hospitals of the Ruhr-University of Bochum), Jeannette Hübener‐Schmid(Universitätsklinikum Tübingen)
Cited by 34
Related Papers
The TRIPOD-LLM reporting guideline for studies using large language models
|Nature Medicine|2025|340
Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3)
|Human Molecular Genetics|2012|78
From Pathways to Targets: Understanding the Mechanisms behind Polyglutamine Disease
|BioMed Research International|2014|70
Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy
|Radiotherapy and Oncology|2020|57